TY - JOUR T1 - Determination of vancomycin exposure target and individualised dosing recommendations for neonates: model-informed precision dosing JF - medRxiv DO - 10.1101/2020.03.30.20045971 SP - 2020.03.30.20045971 AU - Zhe Tang AU - Jing Guan AU - Jingjing Li AU - Yanxia Yu AU - Miao Qian AU - Jiang Cao AU - Weiwei Shuai AU - Zheng Jiao Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/09/10/2020.03.30.20045971.abstract N2 - Few studies incorporating population pharmacokinetic/pharmacodynamic (Pop-PK/PD) modelling have been conducted to quantify the exposure target of vancomycin in neonates. To determine this target and dosing recommendations, a retrospective observational cohort study was established in neonates (chictr.org.cn, ChiCTR1900027919). A Pop-PK model was developed to estimate PK parameters. Causalities between acute kidney injury (AKI) occurrence and vancomycin use were verified using Naranjo criteria. Thresholds of vancomycin exposure in predicting AKI or efficacy were identified via classification and regression tree analysis. Associations between exposure thresholds and clinical outcomes including AKI and efficacy, were analysed by logistic regression. Dosing recommendations were designed using Monte Carlo (MC) simulations based on the optimised exposure target. Pop-PK modelling included 182 neonates with 411 observations. In covariate analysis, neonatal physiological maturation, renal function, and concomitant use of vasoactive drugs (VAS) significantly affected vancomycin pharmacokinetics. Seven cases of vancomycin-induced AKI were detected. Area under the concentration–time curve from 0–24 h (AUC0-24) ≥ 485 mg·h/L was an independent risk factor for AKI after adjusting for VAS co-administration. Clinical efficacy of vancomycin was analysed in 42 patients with blood culture-proven staphylococcal sepsis. AUC0–24 to minimum inhibitory concentration (AUC0–24/MIC) ≥ 234 was the only significant predictor of clinical effectiveness. MC simulations indicated that regimens in Neonatal Formulary 7 and Red Book (2018) were not suitable for all neonates. In summary, AUC0-24 of 240-480 assuming MIC = 1 mg/L is a recommended exposure target of vancomycin in neonates. Model-informed dosing regimens are valuable in clinical practice.HighlightsThe optimised neonatal exposure target of vancomycin was uniquely quantifiedDay 1 exposure of vancomycin is the predictor for clinical outcomes in neonatesVancomycin-induced acute kidney injury is not related to high exposure aloneA lower exposure target is likely to be more effective for neonates than for adultsMonte Carlo simulation provides a more suitable dosing regimen for neonatesCompeting Interest StatementThe authors have declared no competing interest.Clinical TrialThis study has been registered at chictr.org.cn under identifier ChiCTR1900027919Funding StatementThis project was supported by Hospital Pharmacy Foundation of Nanjing Pharmaceutical Association (No. 2019YX004).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data of this study will be open to public through public access of medresman.org.cn within 6 months after publication. http://www.medresman.org.cn/pub/cn/proj/projectshshow.aspx?proj=1448 ER -